Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA, discusses the potential utility of biosimilars in oncology.
Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA
Advertisement
Articles by Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA
Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA, clinical coordinator, Hematology/Oncology, The University of Arizona Cancer Center, clinical assistant professor, The University of Arizona College of Pharmacy, discusses the regulatory pathway for biosimilars in oncology.
Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA, discusses factors that need to be taken into consideration as biosimilars emerge in oncology.
Advertisement
Latest Updated Articles
Dr. McBride on the Emergence of Biosimilars in OncologyPublished: November 27th 2019 | Updated:
Dr. McBride on the Regulatory Pathway for Biosimilars in OncologyPublished: December 3rd 2019 | Updated:
Dr. McBride on the Potential of Biosimilars in OncologyPublished: December 5th 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
4
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
5